Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes mellitus: A report of two cases

Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype

Marchand, L.
Thivolet, A.
Dalle, S.
Chikh, K.
Reffet, S.
Vouillarmet, J.
Fabien, N.
Cugnet-Anceau, C.
Thivolet, C.

January 2019

AIMS: Programmed cell death-1 and programmed death ligand 1 (PD-1/PD-L1) inhibitors restore antitumo...

CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus

Thiago P. Muniz
Daniel V. Araujo
Kerry J. Savage
Tina Cheng
Moumita Saha
Xinni Song
Sabrina Gill
Jose G. Monzon
Debjani Grenier
Sofia Genta
Michael J. Allen
Diana P. Arteaga
Samuel D. Saibil
Marcus O. Butler
Anna Spreafico
David Hogg

December 2021

Immune checkpoint inhibitor (ICI)-induced insulin-dependent diabetes mellitus (IDDM) is a rare but p...

Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes.

Perdigoto, Ana Luisa
Deng, Songyan
Du, Katherine C
Kuchroo, Manik
Burkhardt, Daniel B
Tong, Alexander
Israel, Gary
Robert, Marie E
Weisberg, Stuart P
Kirkiles-Smith, Nancy
Stamatouli, Angeliki M
Kluger, Harriet M
Quandt, Zoe
Young, Arabella
Yang, Mei-Ling
Mamula, Mark J
Pober, Jordan S
Anderson, Mark S
Krishnaswamy, Smita
Herold, Kevan C

September 2022

Checkpoint inhibitors (CPIs) targeting programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) a...

Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes mellitus: A report of two cases

Fujiwara, Noriko
Watanabe, Mayu
Katayama, Akihiro
Noda, Yohei
Eguchi, Jun
Kataoka, Hitomi
Kagawa, Shunsuke
Wada, Jun

September 2021

Immune checkpoint inhibitor-induced diabetes mellitus is a rare immune-related adverse event. This r...

Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review

Filette, J.M.K. de
Pent, J.J.
Decoster, L.
Vissers, T.
Bravenboer, B.
Auwera, B.J. van der
Goruss, F.K.
Roep, B.O.
Aspeslagh, S.
Neyns, B.
Velkeniers, B.
Kharagjitsingh, A.V.

September 2019

Objective: To better define the rare adverse event (AE) of diabetes mellitus associated with immune ...

Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice

Yun Kyung Cho
Chang Hee Jung

November 2023

With the increasing use of immune-checkpoint inhibitors (ICIs), such as anti-cytotoxic T lymphocyte-...

Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature

February 2022

none6noImmune Check-Point Inhibitors (CPIs) have improved long-term patients’ outcomes in several ad...

Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review

Wei Fang
Yang Gao
Xiaoyan Shi
Xiaoran Zhang
Shan Zhou
Hongxia Zhu
Wei Yan
Huanping Wang

September 2023

Immune checkpoint inhibitors (ICIs) are increasingly being used in the treatment of advanced human m...

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.

Stamatouli, Angeliki M
Quandt, Zoe
Perdigoto, Ana Luisa
Clark, Pamela L
Kluger, Harriet
Weiss, Sarah A
Gettinger, Scott
Sznol, Mario
Young, Arabella
Rushakoff, Robert
Lee, James
Bluestone, Jeffrey A
Anderson, Mark
Herold, Kevan C

August 2018

Insulin-dependent diabetes may occur in patients with cancers who are treated with checkpoint inhibi...

Immune checkpoint inhibitor– and phosphatidylinositol-3-kinase inhibitor–related diabetes induced by antineoplastic drugs: two case reports and a literature review

Yue Gao
Yue Gao
Mingyao Zhong
Lulu Gan
Cheng Xiang
Ling Li
Yimin Yan
Yimin Yan

September 2023

Immune checkpoint inhibitor (ICI)- and phosphatidylinositol-3-kinase inhibitor (PI3Ki)-related diabe...

Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.

Zezza, M.
Kosinski, C.
Mekoguem, C.
Marino, L.
Chtioui, H.
Pitteloud, N.
Lamine, F.

December 2019

The use of immune checkpoint inhibitor (ICI) therapy is becoming a standard of care for several canc...

Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment.

Mulla, K
Farag, S
Moore, B
Matharu, S
Young, K
Larkin, J
Popat, S
Morganstein, DL

May 2023

AIMS: We systematically studied the presence of hyperglycaemia during treatment with Immune Checkpoi...

Recovery from insulin dependence in immune checkpoint inhibitor‐associated diabetes mellitus: A case report

Marie Okubo
Yuji Hataya
Kanta Fujimoto
Toshio Iwakura
Naoki Matsuoka

January 2023

ABSTRACT Immune checkpoint inhibitor‐associated diabetes mellitus (ICI‐DM) is a rare immune‐related ...

The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors

Marchand, L.
Disse, E.
Dalle, S.
Reffet, S.
Vouillarmet, J.
Fabien, N.
Thivolet, C.
Cugnet-Anceau, C.

January 2019

Immune checkpoint inhibitors (CPI) are increasingly being used in oncology, and many autoimmune side...

Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer

James Luke Godwin
Shuchie Jaggi
Imali Sirisena
Pankaj Sharda
Ajay D. Rao
Ranee Mehra
Colleen Veloski

May 2017

Abstract Background Advances in cancer immunotherapy have generated encouraging results in multiple ...

Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype

Marchand, L.
Thivolet, A.
Dalle, S.
Chikh, K.
Reffet, S.
Vouillarmet, J.
Fabien, N.
Cugnet-Anceau, C.
Thivolet, C.

January 2019

AIMS: Programmed cell death-1 and programmed death ligand 1 (PD-1/PD-L1) inhibitors restore antitumo...

CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus

Thiago P. Muniz
Daniel V. Araujo
Kerry J. Savage
Tina Cheng
Moumita Saha
Xinni Song
Sabrina Gill
Jose G. Monzon
Debjani Grenier
Sofia Genta
Michael J. Allen
Diana P. Arteaga
Samuel D. Saibil
Marcus O. Butler
Anna Spreafico
David Hogg

December 2021

Immune checkpoint inhibitor (ICI)-induced insulin-dependent diabetes mellitus (IDDM) is a rare but p...

Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes.

Perdigoto, Ana Luisa
Deng, Songyan
Du, Katherine C
Kuchroo, Manik
Burkhardt, Daniel B
Tong, Alexander
Israel, Gary
Robert, Marie E
Weisberg, Stuart P
Kirkiles-Smith, Nancy
Stamatouli, Angeliki M
Kluger, Harriet M
Quandt, Zoe
Young, Arabella
Yang, Mei-Ling
Mamula, Mark J
Pober, Jordan S
Anderson, Mark S
Krishnaswamy, Smita
Herold, Kevan C

September 2022

Checkpoint inhibitors (CPIs) targeting programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) a...

Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes mellitus: A report of two cases

Fujiwara, Noriko
Watanabe, Mayu
Katayama, Akihiro
Noda, Yohei
Eguchi, Jun
Kataoka, Hitomi
Kagawa, Shunsuke
Wada, Jun

September 2021

Immune checkpoint inhibitor-induced diabetes mellitus is a rare immune-related adverse event. This r...

Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review

Filette, J.M.K. de
Pent, J.J.
Decoster, L.
Vissers, T.
Bravenboer, B.
Auwera, B.J. van der
Goruss, F.K.
Roep, B.O.
Aspeslagh, S.
Neyns, B.
Velkeniers, B.
Kharagjitsingh, A.V.

September 2019

Objective: To better define the rare adverse event (AE) of diabetes mellitus associated with immune ...

Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice

Yun Kyung Cho
Chang Hee Jung

November 2023

With the increasing use of immune-checkpoint inhibitors (ICIs), such as anti-cytotoxic T lymphocyte-...

Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature

February 2022

none6noImmune Check-Point Inhibitors (CPIs) have improved long-term patients’ outcomes in several ad...

Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review

Wei Fang
Yang Gao
Xiaoyan Shi
Xiaoran Zhang
Shan Zhou
Hongxia Zhu
Wei Yan
Huanping Wang

September 2023

Immune checkpoint inhibitors (ICIs) are increasingly being used in the treatment of advanced human m...

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.

Stamatouli, Angeliki M
Quandt, Zoe
Perdigoto, Ana Luisa
Clark, Pamela L
Kluger, Harriet
Weiss, Sarah A
Gettinger, Scott
Sznol, Mario
Young, Arabella
Rushakoff, Robert
Lee, James
Bluestone, Jeffrey A
Anderson, Mark
Herold, Kevan C

August 2018

Insulin-dependent diabetes may occur in patients with cancers who are treated with checkpoint inhibi...

Immune checkpoint inhibitor– and phosphatidylinositol-3-kinase inhibitor–related diabetes induced by antineoplastic drugs: two case reports and a literature review

Yue Gao
Yue Gao
Mingyao Zhong
Lulu Gan
Cheng Xiang
Ling Li
Yimin Yan
Yimin Yan

September 2023

Immune checkpoint inhibitor (ICI)- and phosphatidylinositol-3-kinase inhibitor (PI3Ki)-related diabe...

Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.

Zezza, M.
Kosinski, C.
Mekoguem, C.
Marino, L.
Chtioui, H.
Pitteloud, N.
Lamine, F.

December 2019

The use of immune checkpoint inhibitor (ICI) therapy is becoming a standard of care for several canc...

Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment.

Mulla, K
Farag, S
Moore, B
Matharu, S
Young, K
Larkin, J
Popat, S
Morganstein, DL

May 2023

AIMS: We systematically studied the presence of hyperglycaemia during treatment with Immune Checkpoi...

Recovery from insulin dependence in immune checkpoint inhibitor‐associated diabetes mellitus: A case report

Marie Okubo
Yuji Hataya
Kanta Fujimoto
Toshio Iwakura
Naoki Matsuoka

January 2023

ABSTRACT Immune checkpoint inhibitor‐associated diabetes mellitus (ICI‐DM) is a rare immune‐related ...

The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors

Marchand, L.
Disse, E.
Dalle, S.
Reffet, S.
Vouillarmet, J.
Fabien, N.
Thivolet, C.
Cugnet-Anceau, C.

January 2019

Immune checkpoint inhibitors (CPI) are increasingly being used in oncology, and many autoimmune side...

Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer

James Luke Godwin
Shuchie Jaggi
Imali Sirisena
Pankaj Sharda
Ajay D. Rao
Ranee Mehra
Colleen Veloski

May 2017

Abstract Background Advances in cancer immunotherapy have generated encouraging results in multiple ...

Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype

Marchand, L.
Thivolet, A.
Dalle, S.
Chikh, K.
Reffet, S.
Vouillarmet, J.
Fabien, N.
Cugnet-Anceau, C.
Thivolet, C.

January 2019

AIMS: Programmed cell death-1 and programmed death ligand 1 (PD-1/PD-L1) inhibitors restore antitumo...

CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus

Thiago P. Muniz
Daniel V. Araujo
Kerry J. Savage
Tina Cheng
Moumita Saha
Xinni Song
Sabrina Gill
Jose G. Monzon
Debjani Grenier
Sofia Genta
Michael J. Allen
Diana P. Arteaga
Samuel D. Saibil
Marcus O. Butler
Anna Spreafico
David Hogg

December 2021

Immune checkpoint inhibitor (ICI)-induced insulin-dependent diabetes mellitus (IDDM) is a rare but p...

Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes.

Perdigoto, Ana Luisa
Deng, Songyan
Du, Katherine C
Kuchroo, Manik
Burkhardt, Daniel B
Tong, Alexander
Israel, Gary
Robert, Marie E
Weisberg, Stuart P
Kirkiles-Smith, Nancy
Stamatouli, Angeliki M
Kluger, Harriet M
Quandt, Zoe
Young, Arabella
Yang, Mei-Ling
Mamula, Mark J
Pober, Jordan S
Anderson, Mark S
Krishnaswamy, Smita
Herold, Kevan C

September 2022

Checkpoint inhibitors (CPIs) targeting programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) a...

Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes mellitus: A report of two cases

Abstract

Extracted data

Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes mellitus: A report of two cases

Abstract

Extracted data

Related items

Related items